Abattis Bioceuticals (CSE:ATT, Stock Forum) continued to advance its dreams of full-spectrum seed-to-sale aspirations when it announced today that the company had appointed product development veteran, Brazos Minshew to take on the role of president at Biocell.
According to the news release, Minshew will be replacing Mike Withrow so that Withrow can focus on leadership as CEO of Abattis. Mr. Withrow will stay on as Chairman of Biocell.
Mr. Minshew brings with him extensive experience as both CEO of companies such as Samuel J. Brant, LLC and Therapy Alternatives as well as fulfilling the role of Chief Science Officer for TriVita.
He also serves as the chairman of an International Medical Advisory Board that coordinates relief work in areas of desperate need, and has over 200 articles and four articles under his belt in writing Intellectual Properties, such as international patent and trademark applications.
At TriVita, Minshew developed the products, messaging and IP around a pipeline of products totaling close to US$200 million in annual sales.
Minshew had this to say, “As a speaker, writer and teacher I have travelled the world. I have communed with curanderos in Native Reservations and medicine men and women in the Amazon rainforest.”
He went on to illustrate, “I taught pharmacognosy seminars at the School of Pharmacy, Ankara, Turkey, provided Continuing Education to physicians at the Hospital Especialidades in Quetzaltenango, Guatemala, presented nutritional biochemistry at the University of Croatia, School of Pharmacy in Zagreb, Croatia and shared clinical research on cholesterol reduction at the African Conference of Cardiology in Port Louis, Mauritius.”
Then added, “All of this to say that my career focus is to promote Traditional healing practices and revitalize the use of plant-based medicines to relieve human suffering.”
Mike Withrow concluded, “We are all extremely pleased to bring a top caliber speaker, writer, teacher, researcher, and leader to BioCell Labs...He is committed to building on the Abattis reputation as the international leader in cannabis-based medications.”
Abbatis was in the news recently when the company announced receiving a breakthrough nitric oxide WIPO patent publication nine days ago.
Currently there are 57.9m outstanding shares with a market cap of $36.5 million.